Latest Data


« Join The Fight Against Cancer Cambridge Who’s Who Recognizes Dr. Serena M. Bordes For Excellence In Naturopathic Treatment And Oriental Medicine | Main | Subject New European Survey Highlights Need For Improvement In Chronic Myeloid Leukaemia Monitoring (cml) »

New Entry Fda Approves Ge Healthcare’s Adreview (iobenguane I 123 Injection) Diagnostic Agent For Detecting Neuroendocrine Tumors In Children, Adults

By admin2 | November 17, 2008

MedicalGE Healthcare, a unit of General Electric Company (NYSE:GE), announced that the Food and Drug Administration (FDA) has approved AdreView™ (Iobenguane I 123 Injection), a molecular imaging agent for the detection of rare neuroendocrine tumors in children and adults. AdreView provides high quality images that allow physicians to detect tumors, both at the time of initial diagnosis and at later examinations when relapse or recurrence is suspected.
(Link)

This entry was important to me: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • StumbleUpon
  • Digg
  • del.icio.us
  • Reddit
  • Furl
  • Junipo

Topics: Cancer |

Comments